Gopee N H, Charlton F G, Hampton P J
Department of Dermatology Royal Victoria Infirmary Newcastle upon Tyne UK.
Department of Pathology Royal Victoria Infirmary Newcastle upon Tyne UK.
Skin Health Dis. 2021 Mar 31;1(2):e23. doi: 10.1002/ski2.23. eCollection 2021 Jun.
Sweet syndrome (SS) can be categorized as classical Sweet syndrome (CSS), malignancy-associated Sweet syndrome (MASS) or drug-induced Sweet syndrome (DISS). Appropriate categorization of patients with SS and identification of the associated trigger are essential to direct subsequent investigations and follow-up, especially given that 21% of cases are malignancy-associated. However, no published guidelines exist to guide this.
To analyse the categorization, management and outcomes of patients with SS in order to propose a structured approach for investigation and follow-up.
Retrospective data collection from the electronic records of patients diagnosed with SS between 1 January 2005 and 31 December 2018. Categorized and non-categorized patients were compared, and the yield rate of investigations and duration of follow-up were analysed.
Sixty-four patients were included with CSS (77%), MASS (20%) and DISS (3%). Of these, 34 (53%) cases were not categorized by the assessing clinicians, three of which were subsequently diagnosed with a malignancy, up to 19 months later. There was no significant difference in investigations performed between categorized and non-categorized patients and the yield rates were modest overall. Follow-up averaged 10.5 (16.8) months; non-categorized patients were followed-up for significantly longer than categorized patients (15.0 (21.2) vs. 5.4 (6.8) months, < 0.05).
The lack of a structured way to approach patients with SS can lead to under- or over-investigation, diagnostic delays of underlying conditions and unnecessary follow-up. An algorithm is proposed to identify the likely trigger and manage patients accordingly. Larger prospective studies are required to confirm the optimal approach to investigate and follow-up patients with SS.
Sweet综合征(SS)可分为经典型Sweet综合征(CSS)、恶性肿瘤相关Sweet综合征(MASS)或药物性Sweet综合征(DISS)。对SS患者进行恰当分类并识别相关诱因对于指导后续检查和随访至关重要,尤其是考虑到21%的病例与恶性肿瘤相关。然而,目前尚无已发表的指南来指导这一过程。
分析SS患者的分类、管理及预后,以提出一种结构化的检查和随访方法。
回顾性收集2005年1月1日至2018年12月31日期间诊断为SS的患者的电子病历数据。对已分类和未分类的患者进行比较,并分析检查的阳性率和随访时间。
共纳入64例患者,其中CSS占77%,MASS占20%,DISS占3%。其中,34例(53%)病例未被评估医生分类,其中3例随后被诊断为恶性肿瘤,时间间隔长达19个月。已分类和未分类患者之间进行的检查无显著差异,总体阳性率适中。随访平均时间为10.5(16.8)个月;未分类患者的随访时间明显长于已分类患者(15.0(21.2)个月 vs. 5.4(6.8)个月,P<0.05)。
缺乏针对SS患者的结构化处理方法可能导致检查不足或过度、潜在疾病的诊断延迟以及不必要的随访。提出了一种算法来识别可能的诱因并相应地管理患者。需要更大规模的前瞻性研究来确认调查和随访SS患者的最佳方法。